SCHEMBL1476650

SCHEMBL1476650

C#Cc1ccccn1.c1cc2cc-2c1

nearest known ligand 0.48

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 9/20 0.42
KCNH2 Q12809 2/20 0.37
CYP1A2 P05177 2/20 0.36
CLK4 Q9HAZ1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29911538 0.87
SCHEMBL211092 0.87
SCHEMBL9092415 0.85 GRM5 (0.41) GRM5KCNH2CYP1A2
SCHEMBL28163236 0.85
Bromide SCHEMBL31122035 0.85
SCHEMBL28453493 0.85
SCHEMBL27821882 0.85
Anthracene SCHEMBL28212240 0.82 GRM5 (0.46) GRM5KCNH2CYP1A2
Naphthalene SCHEMBL28109656 0.81 GRM5 (0.48) GRM5KCNH2CYP1A2
SCHEMBL3836603 0.77 GRM5 (0.47) GRM5KCNH2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1729771-B1 PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2009-10-14 EP claimed
CN-109776253-B Method for selectively synthesizing cis-olefin and trans-olefin by catalyzing semi-reduction of alkyne through palladium hydrogen donor by alcohol 南通大学 2022-07-15 CN disclosed
US-7915424-B2 Analgesics; anxiolytic agents ELI LILLY AND COMPANY (US) 2011-03-29 US disclosed
US-7667040-B2 Azacyclic ethynyl derivatives NEUROSEARCH A/S (DK) 2010-02-23 US disclosed
EP-1729771-B1 PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2009-10-14 EP disclosed
US-20080194647-A1 Pyridyl Derivatives and Their Use as Mglu5 Antagonists ELI LILLY AND COMPANY (US) 2008-08-14 US disclosed
US-20080188519-A1 Novel azacyclic ethynyl derivatives ANIONA APS (DK) 2008-08-07 US disclosed
EP-1506205-B1 NOVEL AZACYCLIC ETHYNYL DERIVATIVES NEUROSEARCH AS (DK) 2008-07-16 EP disclosed
US-7378526-B2 Azacyclic ethynyl derivatives NEUROSEARCH A/S (DK) 2008-05-27 US disclosed
EP-1729771-A1 PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS Eli Lilly & Company (US) 2006-12-13 EP disclosed
WO-2005094822-A1 PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-10-13 WO disclosed
US-20050171078-A1 Novel azacyclic ethynyl derivatives NEUROSEARCH (DK) 2005-08-04 US disclosed
EP-1506205-A2 NOVEL AZACYCLIC ETHYNYL DERIVATIVES NEUROSEARCH A/S (DK) 2005-02-16 EP disclosed
WO-2003094830-A2 NOVEL AZACYCLIC ETHYNYL DERIVATIVES NEUROSEARCH A/S (DK) 2003-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171078-A1 Novel azacyclic ethynyl derivatives CHRNA6, CHRNA5, CHRNA10 GRM5 172/4885KCNH2 886/4885CYP1A2 1007/4885
US-20080188519-A1 Novel azacyclic ethynyl derivatives CHRNA6, CHRNA10, CHRNA5 GRM5 183/4885KCNH2 1154/4885CYP1A2 1110/4885
US-20080194647-A1 Pyridyl Derivatives and Their Use as Mglu5 Antagonists HRH4, CNR2, CNR1 GRM5 48/4885KCNH2 325/4885CYP1A2 1502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.